Outcomes
death
RECURRENCE, INVASIVE BREAST CANCER, DISEASE, INVASIVE CANCER, BREAST TUMOR, EVENTS
The primary endpoint of the OlympiA trial was IDFS, defined as the time from randomization until the date of the first occurrence of one of the following events: ipsilateral invasive breast tumor, locoregional invasive disease, distant recurrence, contralateral invasive breast cancer (BC), second primary invasive cancer, or death from any cause [An independent external data and safety monitoring committee reviewed the results of the planned first interim analysis of the primary endpoint (IDFS). They recommended proceeding with the analysis and reporting [